Together, this suggests NOX4 regulates PKM2 expression through a PCAF-dependent, acetylation- and lysosomal-mediated mechanism and that PKM2 is the critical NOX4 downstream target involved in RCC drug resistance. This evidence concerns the gene NOX4 and renal cell carcinoma.